文献速递术前评估与围术期医学疼痛医学

丙泊酚全静脉麻醉与结肠癌手术患者生存改善相关

Propofol-based Total Intravenous Anesthesia Is Associated with Better Survival Than Desflurane Anesthesia in Colon Cancer Surgery.
PubMed 文献 · Anesthesiology · 2018-01-01

该回顾性队列研究纳入2005至2014年间接受择期结肠癌手术的患者,比较丙泊酚全静脉麻醉与地氟烷吸入麻醉对生存的影响。经倾向性匹配后,丙泊酚组死亡风险显著低于地氟烷组,且在不同TNM分期及有无转移亚组中均一致。

要点

  • 丙泊酚全静脉麻醉与结肠癌术后更好的生存相关。
  • 匹配后丙泊酚组死亡比例15.0%,地氟烷组32.6%。
  • 生存获益在不同TNM分期和转移状态亚组中均存在。

核心结论

  • 丙泊酚麻醉用于结肠癌手术与更好的生存相关,且不受TNM分期影响。

研究设计与样本

  • 排除接受丙泊酚联合吸入麻醉或硬膜外麻醉者,按麻醉方式分为丙泊酚组和地氟烷组。
  • 经倾向性匹配后,使用单变量和多变量Cox回归模型比较死亡风险比。

主要发现

  • 地氟烷组706例(死亡307例,43.5%),丙泊酚组657例(死亡88例,13.4%)纳入分析。
  • 倾向性匹配后每组579例,地氟烷组死亡189例(32.6%),丙泊酚组死亡87例(15.0%)。
  • 匹配分析中,丙泊酚组在较低TNM分期亚组的风险比0.22(95%CI 0.11-0.42,P<0.001)。
  • 较高TNM分期亚组的风险比0.42(95%CI 0.32-0.55,P<0.001)。
  • 有转移亚组风险比0.67(95%CI 0.51-0.86,P=0.002),无转移亚组风险比0.08(95%CI 0.01-0.62,P=0.016)。

临床怎么用

  • 对于择期结肠癌手术,可考虑优先选择丙泊酚全静脉麻醉,但需结合患者个体情况。

局限性

  • 回顾性队列设计,可能存在未测量的混杂因素。
  • 研究仅纳入单中心数据,外推性需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

WHAT WE ALREADY KNOW ABOUT THIS TOPIC: WHAT THIS ARTICLE TELLS US THAT IS NEW: BACKGROUND:: Previous research has shown different effects of anesthetics on cancer cell growth. Here, the authors investigated the association between type of anesthetic and patient survival after elective colon cancer surgery. METHODS: A retrospective cohort study included patients who received elective colon cancer surgery between January 2005 and December 2014. Patients were grouped according to anesthesia received: propofol or desflurane. After exclusion of those who received combined propofol anesthesia with inhalation anesthesia or epidural anesthesia, survival curves were constructed from the date of surgery to death. After propensity matching, univariable and multivariable Cox regression models were used to compare hazard ratios for death. Subgroup analyses were performed for tumor-node-metastasis staging and postoperative metastasis. RESULTS: A total of 706 patients (307 deaths, 43.5%) with desflurane anesthesia and 657 (88 deaths, 13.4%) with propofol anesthesia were eligible for analysis. After propensity matching, 579 patients remained in each group (189 deaths, 32.6%, in the desflurane group vs. 87, 15.0%, in the propofol group). In the matched analyses, the propofol-treated group had a better survival, irrespective of lower tumor-node-metastasis stage (hazard ratio, 0.22; 95% CI, 0.11 to 0.42; P < 0.001) or higher tumor-node-metastasis stage (hazard ratio, 0.42; 95% CI, 0.32 to 0.55; P < 0.001) and presence of metastases (hazard ratio, 0.67; 95% CI, 0.51 to 0.86; P = 0.002) or absence of metastases (hazard ratio, 0.08; 95% CI, 0.01 to 0.62; P = 0.016). Simple propensity score adjustment produced similar findings. CONCLUSIONS: Propofol anesthesia for colon cancer surgery is associated with better survival irrespective of tumor-node-metastasis stage.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Wu ZF, Lee MS, Wong CS, et al. Propofol-based Total Intravenous Anesthesia Is Associated with Better Survival Than Desflurane Anesthesia in Colon Cancer Surgery. Anesthesiology. 2018. PMID: 30028726. doi:10.1097/ALN.0000000000002357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。